Resolutions from Swedish Orphan Biovitrum AB’s (Sobi™) Annual General Meeting (AGM)

The Sobi AGM convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:

Adoption of the profit and loss statements and balance sheet and discharge of liability

The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,882,438,248.

The board members and the chief executive officer were discharged from liability for the financial year 2015.

Election of Board of Directors, remuneration to the Directors and election of Auditor

The ordinary board members Annette Clancy, Matthew Gantz, Lennart Johansson, Helena Saxon and Hans GCP Schikan were re-elected and Håkan Björklund, Theresa Heggie and Jeffrey Jonas were elected as new board members. Håkan Björklund was elected chairman of the Board.

Håkan Björklund has an extensive international background in the life science industry, from both R&D and sales and marketing. He has experience of leading healthcare companies in expansive development phases. Håkan Björklund owns 15,800 shares in the company and is independent in relation to the company and its management and in relation to the company´s principal shareholders.

Theresa Heggie has several years’ of experience from a number of positions with a global responsibility within, among other things, sales and marketing of pharmaceuticals. Theresa Heggie does not have any shares in the company and is independent in relation to the company and its management and in relation to the company´s principal shareholders.

Jeffrey Jonas has more than 20 years’ of experience from research as well as marketing within the pharmaceuticals and healthcare industries. Jeffrey Jonas does not have any shares in the company and is independent in relation to the company and its management and in relation to the company´s principal shareholders.

The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.

Ernst & Young was re-elected as auditor of Sobi until the end of the AGM 2017.

Principles for remuneration for the management, long-term incentive programme, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares

The AGM approved the proposed guidelines for remuneration for the management.

The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive programme, and hedging arrangements in respect of the programme including a directed issue of no more than 188,142 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,276,826 own common shares to programme participants.

The AGM also approved the Board’s proposal regarding the approval to authorise the Board to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 30,000,000 shares in total.

The Board’s proposal regarding transfer of no more than 303,346 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Programme 2013, was also approved by the AGM.

For full details on each proposal adopted by the AGM please refer to www.sobi.com.

---

About Sobi™
Sobi™ is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ Stockholm. 

For more information please contact

Media   relations   Investor   relations
Oskar   Bosson, Head of Communications Jörgen   Winroth, Vice President, Head of Investor Relations
T:   +46 70 410 71 80 T:   +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson@sobi.com  jorgen.winroth@sobi.com 

The information was released for public distribution on 24 May 2016 at 19:00 CET.

Tags: